The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Successful implementation of a novel trial model: The Signature program.
 
Julio Antonio Peguero
Employment - Oncology Consultants
Speakers' Bureau - Bayer
 
James A. Knost
No Relationships to Disclose
 
Todd Michael Bauer
Research Funding - Novartis (Inst)
 
Matthew Hiram Taylor
Consulting or Advisory Role - Eisai; Onyx; PDX Pharmacy
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Eisai (Inst); Merck KGaA (Inst); Novartis (Inst)
 
Fadi S. Braiteh
Employment - Novartis
Stock and Other Ownership Interests - Celgene; Insys Therapeutics
Honoraria - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Consulting or Advisory Role - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Genomic Health; Incyte; Insys Therapeutics; Myriad Pharmaceuticals; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Active Biotech (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BIND Therapeutics (Inst); Biomarin (Inst); bioTheranostics (Inst); BN ImmunoTherapeutics (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Cell Therapeutics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Foundation Medicine (Inst); Genomic Health (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); HERON (Inst); ImClone Systems (Inst); Incyte (Inst); Insys Therapeutics (Inst); Janssen (Inst); Lilly (Inst); MEI Pharma (Inst); Merrimack (Inst); Millennium (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); PSMA Development Company (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Viamet Pharmaceuticals (Inst)
 
Joseph Paul Eder
Honoraria - Astellas Pharma; MedImmune
 
Howard Safran
No Relationships to Disclose
 
Bert H. O'Neil
Consulting or Advisory Role - Acceleron Pharma; Amgen; Genentech/Roche; Lilly/ImClone; Sanofi
Speakers' Bureau - Amgen
Research Funding - Novartis (Inst)
 
Ajjai Shivaram Alva
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Research Funding - BIND Biosciences; Bristol-Myers Squibb; Genentech; Novartis; Oncogenex
 
Lincoln Nadauld
Stock and Other Ownership Interests - TOMA Biosciences
Travel, Accommodations, Expenses - Bio-Rad
 
Prashant Joshi
Employment - Novartis
 
Flora Miranda
Travel, Accommodations, Expenses - Novartis
 
Rajinder Sidhu
No Relationships to Disclose
 
Joy Ero
Travel, Accommodations, Expenses - Novartis
 
Eric Daniel Slosberg
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Claudia Lebedinsky
Employment - Novartis
 
Barinder Kang
Employment - Novartis
 
Sudha Parasuraman
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sarina Anne Piha-Paul
Research Funding - Biomarin; GlaxoSmithKline; Helix BioPharma; Merck; Novartis; Puma Biotechnology